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Objective: To determine the potential role of steroid therapy combined with early antiviral and supportive care in 
patients infected with human immunodeficiency virus (HIV) with varicella pneumonia. 
Materials and Methods: A retrospective review was conducted of the incidence, clinical course, and outcome of vari- 
cella pneumonia in patients with HIV or acquired immunodeficiency syndrome (AIDS). 
Results: Seven of 12 patients (58%) who were hospitalized with chickenpox developed clinically severe varicella 
pneumonia. All patients had advanced immunosuppression and all developed diffuse reticulonodular radiographic 
abnormalities, although two patients had normal chest radiographs on admission. All patients received antiviral 
therapy within 12 hours of hospital admission. The overall mortality rate was 43%. Six patients were treated with 
systemic corticosteroids in addition to antiviral agents, including all four of the survivors. 
Conclusions: Hospitalized patients with HIV or AIDS with chickenpox are at high risk for developing varicella 
pneumonia. There is a potentially high rate of death despite prompt initiation of appropriate antiviral therapy. Inten- 
sive care management and adjunctive use of systemic corticosteroids may improve outcome. 
Int J Infect Dis 2002; 6: 6-8 
Pneumonia is the most serious complication of primary 
varicella infection, and the leading cause of death 
in both immunocompetent and immunosuppressed 
adults with chickenpox. 1-3 Varicella is perhaps no more 
common in patients infected with human immuno- 
deficiency virus (HIV) than in healthy adults, but little 
is known about the incidence and clinical course of 
varicella pneumonia in HIV-infected individuals.@ This 
report presents seven cases of clinically severe varicella 
pneumonia that occurred among 12 HIV-infected 
patients with chickenpox who were ill enough to be 
admitted to a tropical disease hospital in South Africa. 
The high incidence of lower respiratory tract involve- 
ment (58%) in this patient population, and the poor 
response to early initiation of acyclovir therapy 
prompted a review the literature on the subject. In light 
of previous experience with the adjunctive use of corti- 
costeroids in normal adult patients with life-threatening 
varicella pneumonia,7 the potential role of steroid 
therapy combined with early antiviral and supportive 
care in HIV-infected patients with this complication is 
discussed. 
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MATERIALS AND METHODS 
This study was conducted at the Sizwe Tropical 
Diseases Hospital, a 500-bed provincial hospital 
affiliated with the University of the Witwatersrand in 
Johannesburg, South Africa. Tuberculosis and HIV 
infection are the most frequent cases seen at this 
hospital; arterial blood gas analysis and intensive care 
(ICU) facilities are not available. A retrospective 
review was conducted of the inpatient medical records 
of 20 adult patients admitted between January 1997 and 
April 1998 who were diagnosed with chickenpox. In all 
patients, HIV status was determined by seropositivity 
on enzyme-linked immunosorbent assay (ELISA) and 
Western blot antibody testing. This study was approved 
by the Committee for Research on Human Subjects at 
the University of the Witwatersrand. 
RESULTS 
Of the 12 patients hospitalized with chickenpox (all 
with fever and multiple cutaneous lesions), seven (58%) 
developed clinically severe varicella pneumonia. CD4+ 
lymphocyte counts ranged from 12 to 250 cell/mm3 
(mean, 82 cells/mm3). Mean patient age was 29 years 
(range, 24-34 y). Clinical and radiographic features and 
outcomes for all patients are summarized in Table 1. 
Two patients (patients 1 and 2) had normal chest 
radiographs upon admission and were started on oral 
famciclovir and parenteral acyclovir, respectively. Both 
developed bilateral reticulonodular pulmonary infil- 
trates within 4 days of starting antiviral therapy. One of 
these patients died 5 days after admission, and the other 
developed pneumococcal pneumonia as a superinfec- 
tion but survived. Five patients were admitted with 
diffuse interstitial infiltrates on chest radiographs 
typical of varicella pneumonia. Two of these patients 
(patients 3 and 4) died 1 and 2 days, respectively, after 
initiation of antiviral therapy. 
All patients received antiviral therapy within 12 
hours of hospital admission. Six patients were also 
treated with systemic corticosteroids: four received oral 
prednisone alone (60 mg/d for 2-4 d; mean, 3.5 d) and 
two were given intravenous hydrocortisone (patient 1, 
200 mg as a single dose followed by oral prednisone 60 
mg/d for two days; patient 4,100 mg every 6 hours for 
two days). Patient 4 subsequently died. The overall 
mortality rate was 43% (3/7 patients). All four of the 
survivors (100%) were given corticosteroids in addition 
to acyclovir, whereas two of three patients (67%) who 
died had received steroids (difference not statistically 
significant). 
DISCUSSION 
Although infection with the varicella-zoster virus is a 
frequent opportunistic occurrence in adults with HIV 
or AIDS, primary varicella infection is relatively rare. 
Children with HIV infection seem to have less virulent 
primary varicella infections, with a lower incidence of 
pulmonary involvement and a better rate of survival.6 
The typical presentation of varicella pneumonia in HIV 
or AIDS involves fever, cough, dyspnea, chest pain, 
and a characteristic vesiculopustular skin rash. The 
chest radiograph invariably shows a diffuse interstitial 
(typically nodular) or alveolar pattern. Hypoxia may 
occur more frequently in HIV-infected patients than in 
immunocompetent persons.4 Although several studies 
have suggested that smoking is a risk factor for varicella 
pneumonia,8-10 smoking histories were not available for 
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the patients in this series. Polymerase chain reaction 
testing of respiratory secretions has been used for diag- 
nostic confirmation of chickenpox pneumonia in HIV 
and AIDS, and may give a positive result even when 
respiratory tract viral cultures are negative.4 Recurrent 
varicella pneumonia requiring acute treatment followed 
by secondary antiviral prophylaxis has been described, 
analogous to other AIDS-complicating opportunistic 
infections.5 
Immunocompromised patients with varicella pneu- 
monia frequently do poorly, with mortality as high as 
45%.11 In this series, the mortality rate from varicella 
pneumonia in HIV-infected patients was 43%, despite 
prompt antiviral treatment; this may, at least in part, 
relate to the lack of ICU availability. All four patients 
who survived were treated with steroids, and although 
this was not significantly different from patients who 
died (2 of 3 received steroids), it is the authors’ clinical 
impression that corticosteroid therapy may confer some 
benefit in clinically severe varicella among HIV- 
infected patients. A 1998 report described six previously 
well patients with life-threatening varicella pneumonia 
and respiratory failure who were managed success- 
fully with intravenous acyclovir, systemic steroids, 
and appropriate supportive care including mechanical 
ventilation.7 These patients demonstrated a clinically 
significant therapeutic response compared with control 
subjects who were treated in the same manner but 
without adjunctive corticosteroids. Steroid-treated 
patients had significantly shorter hospital and ICU 
stays, and there was no mortality despite the fact that 
they were admitted to the ICU with significantly lower 
median ratios of Pa02 and fraction of inspired oxygen 
(PaOz:FiO$ (86.5 versus 129.5; higher PaOz:FiOz ratios 
indicate more severe impairment of pulmonary gas 
exchange) than those patients who did not receive 
Table 1. Clinical and radiographic features and outcomes of seven HIV-seropositive patients with varicella pneumonia 
Oxygen Saturation (%) 
Age (Y) 
Patient Gender Appearance* On Admission With Deterioration Treatment Outcome 
1 27 Bilateral nodular 97 49 Famciclovir (PO) Death 
M infiltrate then acyclovir (iv) 
plus steroids 
2 34 Bilateral reticulo- 98 71 Acyclovir (iv) Recovery 
M nodular infiltrate plus steroids 
3 24 Bilateral reticulo- 82 - Valaciclovir (po) Death 
M nodular infiltrate 
4 34 Bilateral reticulo- 90 - Acyclovir (iv) Death 
M nodular infiltrate plus steroids 
5 26 Bilateral reticulo- 90 - Acyclovir (iv) Recovery 
M nodular infiltrate plus steroids 
6 30 Bilateral reticulo- 87 68 Acyclovir (iv) Recovery 
M nodular infiltrate plus steroids 
7 29 Bilateral reticulo- 87 - Acyclovir (iv) Recovery 
M nodular infiltrate plus steroids 
*Chest radiograph. po=orally; iv=intravenously. 
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corticosteroid therapy. These patients also demon- 
strated more rapid radiologic improvement, and it is 
believed that this favorable clinical outcome is attribut- 
able to the adjunctive use of steroids. Experience 
suggests that HIV-infected patients with severe life- 
threatening varicella pneumonia and requiring ICU 
admission respond to corticosteroid therapy in the 
same fashion as immunocompetent individuals (Mer M. 
Personal communication). 
CONCLUSION 
Patients with HIV or AIDS who are hospitalized with 
chickenpox are at high risk for developing varicella 
pneumonia. The 58% incidence seen in the present 
study is higher than that from previously reported 
series. There is a potentially high rate of death despite 
prompt initiation of appropriate antiviral therapy. 
Intensive care management and adjunctive use of 
systemic corticosteroids may improve outcomes. 
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